"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Descriptor ID |
D018941
|
MeSH Number(s) |
D23.050.301.264.035.119 D23.050.301.264.051.119 D23.050.301.500.600.200 D23.050.705.552.600.200 D23.101.100.110.119 D23.101.100.150.119
|
Concept/Terms |
Antigens, CD19- Antigens, CD19
- CD19 Antigens
- B Cell Antigen CD19
- CD19 Antigen
- Antigen, CD19
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD19 [D23.050.301.264.035.119]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD19 [D23.050.301.264.051.119]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Antigens, CD19 [D23.050.301.500.600.200]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Antigens, CD19 [D23.050.705.552.600.200]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD19 [D23.101.100.110.119]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD19 [D23.101.100.150.119]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".
This graph shows the total number of publications written about "Antigens, CD19" by people in this website by year, and whether "Antigens, CD19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 1 | 0 | 1 |
1996 | 1 | 0 | 1 |
1998 | 2 | 1 | 3 |
1999 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 1 | 0 | 1 |
2003 | 0 | 2 | 2 |
2004 | 0 | 3 | 3 |
2005 | 0 | 2 | 2 |
2006 | 1 | 4 | 5 |
2007 | 1 | 1 | 2 |
2008 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 3 | 6 | 9 |
2011 | 4 | 5 | 9 |
2012 | 2 | 2 | 4 |
2013 | 5 | 1 | 6 |
2014 | 4 | 7 | 11 |
2015 | 2 | 2 | 4 |
2016 | 3 | 5 | 8 |
2017 | 4 | 6 | 10 |
2018 | 6 | 3 | 9 |
2019 | 3 | 6 | 9 |
2020 | 10 | 9 | 19 |
2021 | 6 | 15 | 21 |
2022 | 0 | 33 | 33 |
2023 | 2 | 29 | 31 |
2024 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD19" by people in Profiles.
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241.
-
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May; 99(5):880-889.
-
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar 01; 5(2):106-113.
-
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.
-
Adoptive cellular therapy after hematopoietic stem cell transplantation. Am J Hematol. 2024 May; 99(5):910-921.
-
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784.
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymphoma. 2024 Mar; 65(3):323-332.
-
Management of aggressive lymphoma after CAR T-cell therapy failure. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):364-369.
-
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):91-96.
-
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023 11 28; 7(22):6990-7005.